Vertex to sell European telaprevir milestone rights
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals plans to raise cash through the sale of rights to certain milestone payments tied to the development and commercialisation of its promising hepatitis C virus (HCV) protease inhibitor drug candidate, telaprevir, in Europe. The buyer has not yet been named.